Emerging biotechnology company advancing multi-pMHC targeted T cell engagers to address

新兴生物技术公司，致力于开发多pMHC靶向的T细胞接合器以应对

tumor heterogeneity and resistance

肿瘤异质性和耐药性

Differentiated approach integrates proprietary T cell receptor (TCR) specificity engineering and

差异化方法整合了专有的T细胞受体（TCR）特异性工程和

stabilization technologies to enable precise targeting of intracellular cancer antigens

稳定化技术，以实现对细胞内癌抗原的精确靶向

Lead program DBXO-1 is designed to expand patient eligibility and improve durability of

铅程序DBXO-1旨在扩大患者适应症并提高耐用性

response across major solid tumor indications

在主要实体瘤适应症中的反应

CAMBRIDGE, Mass.

马萨诸塞州剑桥市

,

，

April 9, 2026

2026年4月9日

/PRNewswire/ --

/PRNewswire/ --

Deck Bio

甲板生物

today launches with a multi-target approach designed to expand the reach of T cell engagers in solid tumors by addressing tumor heterogeneity and resistance. Founded by Jack Silberstein, Ph.D., a Stanford-trained protein engineer, Deck Bio is advancing differentiated T cell engagers (TCEs) designed to overcome key limitations of current immuno-oncology approaches and expand the impact of immunotherapy in solid tumors.

今天，该公司推出了一种多靶点策略，旨在通过解决肿瘤异质性和耐药性问题，扩大T细胞结合剂在实体瘤中的应用范围。Deck Bio由斯坦福大学培养的蛋白质工程师杰克·西尔伯斯坦博士创立，公司正在推进差异化的T细胞结合剂（TCE），旨在克服当前免疫肿瘤学方法的关键局限性，并扩大免疫疗法在实体瘤中的影响。

Preclinical data will be presented by Johanna Kaufmann, Ph.D., Deck Bio's Chief Scientific Officer, at the upcoming .

乔安娜·考夫曼博士（Johanna Kaufmann, Ph.D.），Deck Bio公司的首席科学官，将在即将举行的会议上展示临床前数据。

American Association for Cancer Research (AACR) Annual Meeting 2026

美国癌症研究协会（AACR）2026年年会

, taking place April 17–22 in San Diego, California.

，将于4月17日至22日在加利福尼亚州圣地亚哥举行。

While immuno-oncology therapies have transformed cancer treatment, a significant unmet need remains for broader patient populations. TCEs have shown clinical efficacy in hematologic cancers, but their impact on solid tumors remains limited due to tumor heterogeneity, antigen escape, and limited availability of suitable targets..

虽然免疫肿瘤学疗法已经改变了癌症治疗，但对于更广泛的患者群体而言，仍然存在显著的未满足需求。TCE在血液癌症中展现了临床疗效，但由于肿瘤异质性、抗原逃逸以及合适靶点的有限可用性，其对实体瘤的影响仍然有限。

To overcome these challenges, Deck Bio is developing first-in-class TCEs that target tumor-exclusive peptide–major histocompatibility complex (pMHC) proteins, enabling access to a broad range of cancer-driving targets inside the cell that are not reachable with conventional biologics. Unlike first-generation T cell engagers that rely on single antigen targets, the company's therapeutic candidates are designed to recognize multiple tumor-specific targets through a single engineered binder.

为了克服这些挑战，Deck Bio公司正在开发首创的T细胞接合器（TCE），靶向肿瘤专属的肽-主要组织相容性复合体（pMHC）蛋白，从而能够触及传统生物制剂无法到达的广泛细胞内致癌靶点。与依赖单一抗原靶点的第一代T细胞接合器不同，该公司的治疗候选药物设计通过单一工程结合物识别多个肿瘤特异性靶点。

This approach is designed to improve tumor specificity, expand patient eligibility, and reduce the risk of resistance, without the complexity of multi-component therapeutic formats..

这种方法旨在提高肿瘤特异性、扩大患者适用范围并降低耐药风险，同时避免了多组分治疗形式的复杂性。

'Deck Bio was founded to tackle fundamental challenges in targeting cancer, including the limitations of single-antigen approaches and the difficulty of safely accessing intracellular targets,' said

“Deck Bio 成立的宗旨是解决针对癌症的一些根本性挑战，包括单抗原方法的局限性和安全获取细胞内靶点的困难，”

Jack Silberstein, Ph.D.

杰克·西尔伯斯坦，博士

, Founder & Chief Executive Officer of Deck Bio. 'We believe a multi-target approach can help stack the odds in favor of patients, and we are taking a deliberate, capital-efficient approach to development, focusing from the outset on the attributes that matter most for patients and clinicians, including safety, patient access, and durability of response.'.

Deck Bio的创始人兼首席执行官表示：“我们相信多靶点方法可以帮助增加患者的胜算，我们正在采取一种深思熟虑且资本高效的研发方式，从一开始就专注于对患者和临床医生最重要的特性，包括安全性、患者可及性和反应的持久性。”

Underlying this approach is a proprietary platform that integrates a stabilized T cell receptor domain (dbTv™) with a T cell engaging arm to create its T cell engager format (dbTCE™), designed for antibody-like stability and manufacturability. This is complemented by a sequence-agnostic specificity profiling platform (dbSCOPE™), which assesses off-target interactions and guides the design of highly selective therapies..

支撑这一方法的是一个专有平台，该平台将稳定的T细胞受体结构域（dbTv™）与T细胞结合臂整合起来，创建其T细胞接合器形式（dbTCE™），旨在实现类似抗体的稳定性和可制造性。此外，还辅以一个序列不可知的特异性分析平台（dbSCOPE™），用于评估脱靶相互作用并指导高选择性疗法的设计。

'Our goal is to expand the reach of T cell engagers in solid tumors, where patients continue to face significant unmet need,' said

“我们的目标是扩大T细胞结合剂在实体瘤中的应用范围，因为患者在此领域仍然面临显著的未满足需求，”表示

Johanna Kaufmann, Ph.D.

约翰娜·考夫曼，博士

, Chief Scientific Officer of Deck Bio. 'By combining multi-target recognition with deep specificity profiling and improved molecular stability, we are building a platform designed to improve both efficacy and safety, while also enabling scalable manufacturing, all key factors for delivering meaningful patient benefit.'.

Deck Bio的首席科学官表示：“通过将多靶点识别与深度特异性分析和分子稳定性改进相结合，我们正在构建一个旨在提高疗效和安全性的平台，同时也使规模化生产成为可能，这些都是为患者带来有意义益处的关键因素。”

Since its founding in 2023, Deck Bio has raised approximately $3.1 million in funding from Mission BioCapital, the American Cancer Society's venture arm BrightEdge, and Impact Ventures Partners Fund, and has received additional support from leading industry organizations. The company's launch comes at a time of increasing industry focus on next-generation T cell engagers designed to overcome the limitations of earlier approaches in oncology and beyond..

自 2023 年成立以来，Deck Bio 已从 Mission BioCapital、美国癌症协会的风险投资部门 BrightEdge 和 Impact Ventures Partners 基金筹集了大约 310 万美元的资金，并获得了来自领先行业组织的额外支持。该公司推出之际，正值行业对下一代 T 细胞接合器的关注日益增加，这些接合器旨在克服早期在肿瘤学及其他领域方法的局限性。

The company's lead program, DBXO-1, is a multi-target T cell engager being developed for solid tumor indications, including non-small cell lung cancer and gastroesophageal cancer. Additional details will be highlighted during the upcoming presentation at the AACR Annual Meeting 2026.

公司的主要项目DBXO-1是一种多靶点T细胞接合器，正在开发用于实体瘤适应症，包括非小细胞肺癌和胃食管癌。更多细节将在2026年AACR年会的即将举行的演讲中重点介绍。

Conference Presentation Details:

会议报告详情：

Session Title: T Cell Engagers 1 (PO.IM01.16)

会议标题：T细胞结合剂1 (PO.IM01.16)

Abstract Title: Preclinical characterization of DBXO-1, a multi-pMHC targeted bispecific T cell engager for major solid tumors

摘要标题：DBXO-1 的临床前特性研究，一种针对主要实体瘤的多 pMHC 靶向双特异性 T 细胞接合器

Date: April 20, 2026

日期：2026年4月20日

Time: 9:00 a.m. - 12:00 p.m. PST

时间：上午9:00 - 上午12:00（太平洋标准时间）

Poster ID: 1632

海报 ID：1632

About Deck Bio

关于Deck Bio

Deck Bio is a biotechnology company developing novel immunotherapies to unlock the potential of T cell engagers in solid tumors. The company is advancing a differentiated platform of multi-pMHC targeted T cell engagers designed to improve safety, patient access, and durability of response. Its approach integrates a proprietary T cell receptor stabilization technology (dbTv™), a developable T cell engager format (dbTCE™), and a peptidome-wide specificity profiling platform (dbSCOPE™).

Deck Bio是一家生物技术公司，致力于开发新型免疫疗法，以释放T细胞结合剂在实体瘤中的潜力。该公司正在推进一种差异化的多pMHC靶向T细胞结合剂平台，旨在提高安全性、患者可及性和治疗反应的持久性。其方法整合了专有的T细胞受体稳定技术（dbTv™）、可开发的T细胞结合剂形式（dbTCE™）以及全肽组特异性分析平台（dbSCOPE™）。

The company's lead program, DBXO-1, is advancing through preclinical studies and is being developed for major solid tumor indications. Headquartered in Cambridge, Massachusetts, Deck Bio is committed to advancing innovative therapies to address significant unmet needs in cancer..

该公司的主要项目DBXO-1正在推进临床前研究，并正在为重要的实体瘤适应症进行开发。Deck Bio总部位于马萨诸塞州剑桥市，致力于推进创新疗法，以满足癌症领域显著未满足的需求。

For more information, visit

欲了解更多信息，请访问

deck.bio

deck.bio

and follow us on

关注我们

LinkedIn

领英

.

。

SOURCE Deck Bio, Inc.

来源：Deck Bio, Inc.

21

21

%

%

more press release views with

更多新闻稿浏览量与

Request a Demo

请求演示